Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bioventus (BVS) EBITDA Margin (2020 - 2025)

Bioventus' EBITDA Margin history spans 6 years, with the latest figure at 12.28% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 2214.0% year-over-year to 12.28%; the TTM value through Dec 2025 reached 4.85%, up 1529.0%, while the annual FY2025 figure was 4.95%, 1388.0% up from the prior year.
  • EBITDA Margin reached 12.28% in Q4 2025 per BVS's latest filing, up from 1.51% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 29.08% in Q2 2021 to a low of 116.44% in Q2 2023.
  • Average EBITDA Margin over 5 years is 14.44%, with a median of 3.94% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: tumbled -10357bps in 2023, then soared 11230bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 1.48% in 2021, then tumbled by -3992bps to 60.43% in 2022, then surged by 45bps to 33.13% in 2023, then surged by 70bps to 9.86% in 2024, then soared by 225bps to 12.28% in 2025.
  • Per Business Quant, the three most recent readings for BVS's EBITDA Margin are 12.28% (Q4 2025), 1.51% (Q3 2025), and 5.92% (Q2 2025).